Andrew Pecora, MD, FACP, CPE

Dr. Pecora on Updated MAIA Data in Multiple Myeloma

June 20th 2019

Andrew Pecora, MD, FACP, CPE, president physician enterprise, chief innovation officer, John Theurer Cancer Center, Hackensack Meridian Health, discusses the impact age has on the efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (DRd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) as part of the MAIA study.